Red Light-Responsive Upconverting Nanoparticles for Quantitative and Controlled Release of a Coumarin-Based Prodrug.

Fiche publication

Date publication

octobre 2022

Journal

Advanced healthcare materials

Auteurs

Membres identifiés du Cancéropôle Est :
Dr FRISCH Benoit , Dr HEURTAULT Béatrice , Dr KICHLER Antoine , Dr SPECHT Alexandre

Tous les auteurs :
Brion A, Chaud J, Léonard J, Bolze F, Chassaing S, Frisch B, Heurtault B, Kichler A, Specht A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36222265

Résumé

Photolytic reactions allow the optical control of the liberation of biological effectors by photolabile protecting groups. The development of versatile technologies enabling the use of deep-red or NIR light excitation still represents a challenging issue, in particular for light-induced drug release (eg; light induced prodrug activation). Here, we present light-sensitive biocompatible lipid nanocapsules able to liberate an antitumoral drug through photolysis. We demonstrate that original photon upconverting nanoparticles (LNC-UCs) chemically conjugated to a coumarin-based photocleavable linker can quantitatively and efficiently release a drug by upconversion luminescence-assisted photolysis using a deep-red excitation wavelength. In addition, we were also able to demonstrate that such nanoparticles are stable in the dark, without any drug leakage in the absence of light. These findings open new avenues to specifically liberate diverse drugs using deep-red or NIR excitations for future therapeutic applications in nanomedicine.) This article is protected by copyright. All rights reserved.